Aspira Women's Health (AWH) 10-Q 14 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Transition Report	false
Entity File Number	001-34810
Entity Registrant Name	Vermillion, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0595156
Entity Address, Address Line One	12117 Bee Caves Road
Entity Address, Address Line Two	Building Three
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78738
City Area Code	512
Local Phone Number	519-0400
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	VRML
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		97,377,890
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000926617
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 8,132,000	$ 11,703,000
Accounts receivable	946,000	924,000
Prepaid expenses and other current assets	845,000	758,000
Inventories	63,000	25,000
Total current assets	9,986,000	13,410,000
Property and equipment, net	318,000	353,000
Other assets	49,000	65,000
Total assets	10,353,000	13,828,000
Current liabilities:
Accounts payable	1,595,000	1,158,000
Accrued liabilities	2,164,000	2,588,000
Short-term debt	194,000	193,000
Other current liabilities	32,000	39,000
Total current liabilities	3,985,000	3,978,000
Total liabilities	5,051,000	5,090,000
Non-current liabilities:
Long-term debt	1,050,000	1,099,000
Other non-current liabilities	16,000	13,000
Commitments and contingencies (Note 3)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at March 31, 2020 and December 31, 2019
Common stock, par value $0.001 per share, 150,000,000 shares authorized at March 31, 2020 and December 31, 2019; 97,288,657 and 97,286,157 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	97,000	97,000
Additional paid-in capital	431,072,000	430,802,000
Accumulated deficit	(425,867,000)	(422,161,000)
Total stockholders' equity	5,302,000	8,738,000
Total liabilities and stockholders' equity	$ 10,353,000	$ 13,828,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Condensed Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	97,288,657	97,286,157
Common stock, shares outstanding	97,288,657	97,286,157

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Revenue:
Revenue		$ 1,220	$ 803
Cost of revenue:
Cost of revenue		800	694
Gross profit		420	109
Operating expenses:
Research and development	[1]	395	209
Sales and marketing	[1]	2,115	2,364
General and administrative	[1]	1,710	1,255
Total operating expenses		4,220	3,828
Loss from operations		(3,800)	(3,719)
Interest income, net		8	7
Other income (expense), net		86	(4)
Net loss		$ (3,706)	$ (3,716)
Net loss per share - basic and diluted		$ (0.04)	$ (0.05)
Weighted average common shares used to compute basic and diluted net loss per common share		97,287,461	75,507,532
Product [Member]
Revenue:
Revenue		$ 1,210	$ 779
Cost of revenue:
Cost of revenue	[1]	795	516
Service [Member]
Revenue:
Revenue		10	24
Cost of revenue:
Cost of revenue	[1]	$ 5	$ 178
[1]	Non-cash stock-based compensation expense included in cost of revenue and operating expenses

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cost Of Revenue [Member]
Stock-based compensation expense	$ 25	$ 16
Research And Development [Member]
Stock-based compensation expense		2
Sales And Marketing [Member]
Stock-based compensation expense	42	22
General And Administrative [Member]
Stock-based compensation expense	$ 202	$ 144

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2018		75,501,394
Balance at Dec. 31, 2018		$ 75	$ 414,001	$ (406,924)	$ 7,152
Net loss				(3,716)	(3,716)
Common stock issued in conjunction with exercise of stock options (in shares)		19,687
Common stock issued in conjunction with exercise of stock options			17		17
Common stock issued for restricted stock awards (in shares)		11,667
Common stock issued for restricted stock awards			3		3
Stock compensation charge			181		181
Balance (in shares) at Mar. 31, 2019		75,532,748
Balance at Mar. 31, 2019		$ 75	414,202	(410,640)	3,637
Balance (in shares) at Dec. 31, 2019		97,286,157
Balance at Dec. 31, 2019		$ 97	430,802	(422,161)	8,738
Net loss				(3,706)	(3,706)
Common stock issued in conjunction with exercise of stock options (in shares)		2,500
Common stock issued in conjunction with exercise of stock options			1		1
Stock compensation charge			269		269
Balance (in shares) at Mar. 31, 2020		97,288,657
Balance at Mar. 31, 2020		$ 97	$ 431,072	$ (425,867)	$ 5,302

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (3,706)	$ (3,716)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	56	124
Stock-based compensation expense	269	184
Loss on sale and disposal of property and equipment	2	1
Changes in operating assets and liabilities:
Accounts receivable	(111)	87
Prepaid expenses and other assets	14	(43)
Inventories	(38)	(6)
Accounts payable, accrued liabilities and other liabilities	13	261
Net cash used in operating activities	(3,501)	(3,108)
Cash flows from investing activities:
Purchase of property and equipment	(23)	(49)
Proceeds from sale of property and equipment		1
Net cash used in investing activities	(23)	(48)
Cash flows from financing activities:
Principal repayment of DECD loan	(48)	(47)
Proceeds from issuance of common stock from exercise of stock options	1	17
Net cash used in financing activities	(47)	(30)
Net decrease in cash and cash equivalents	(3,571)	(3,186)
Cash and cash equivalents, beginning of period	11,703	9,360
Cash and cash equivalents, end of period	8,132	6,174
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	9	11
Supplemental disclosure of noncash investing and financing activities:
Net increase in other assets/other liabilities for right of use assets	$ 1	$ 147

Organization, Basis Of Presenta

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	3 Months Ended
	Mar. 31, 2020
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company ,” “we,” “our ,” or “us”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1,Overa and OVA1PLUS risk of malignancy tests for ovarian cancer (“OVA1,” “Overa,” and “OVA1PLUS,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. The Company has historically also offered in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD was a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. The Company has discontinued pursuing contracts for ASPiRA IVD and its contractual commitments were concluded in the fourth quarter of 2019. Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $425,867,000 and limited liquidity at March 31, 2020. The Company also expects to incur a net loss and negative cash flows from operations for 2020. Given these conditions, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date these consolidated financial statements are issued . The consolidated financial statements have been prepared on a going concern basis and do not contain any adjustments as a result of these uncertainties . In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. In addition, many conventions and industry conferences have been canceled. As a result of the COVID-19 pandemic and actions taken to contain it, our test volume , and resulting revenue, has decreased significantly in late March and April 2020 as fewer patients are visiting their physicians and elective surgeries have been postponed as a result of closures. A lthough we have seen some increases in late April and early May 2020 , it is uncertain what the duration of the decreased test volumes might be. In order to reduce the impact of limitations on visiting physician offices due to the current closures and quarantines, we have implemented other means of coverage such as virtual sales representative meetings and increased digital sales and marketing. E nrollment for future studies may also be delayed due to the impact of current closures. The full impact of the COVID-19 pandemic continues to evolve as of the date of this filing. As a result, we are unable to estimate the extent of the impact of the COVID-19 pandemic on our liquidity. As discussed in Note 4, on June 28, 2019, the Company completed a public offering (the “Offering”), pursuant to which certain investors purchased Vermillion common stock for net proceeds of approximately $13,521,000 after deducting underwriting discounts, commissions and other expenses related to the offering. On July 2, 2019, William Blair & Company, L.L.C., the sole underwriter of the Offering, exercised its option to purchase additional shares of Vermillion common stock for net proceeds of $2,092,000 , after deducting underwriting discounts, commissions and other expenses related to the offering. As discussed in Note 3, in March 2016, the Company entered into an agreement (as amended, the “Loan Agreement”), pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty. As discussed in Note 3, on May 1, 2020, the Company obtained a loan (the “PPP Loan”) from BBVA USA in the aggregate amount of $1,005,767 , pursuant to the Paycheck Protection Program (the “PPP”), which was established under the Coronavirus Aid, Relief, and Economic Security Act (the “ CARES Act”), as administered by the U.S. Small Business Administration (the “SBA”).  Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2019 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on April 7, 2020 (the “2019 Annual Report”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. In August 2018, the Financial Accounting Standards Board (the “ FASB ”) issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 effective on January 1, 2020, using the prospective transition approach, which allows the Company to change the accounting method without restating prior periods or booking cumulative adjustments. The adoption of ASU 2018-15 did not have a material impact on the Company’s consolidated financial statements.  Significant Accounting and Reporting Policies Revenue Recognition Product Revenue – OVA1, Overa and OVA1PLUS: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ ASC 606”) . Product revenue is recognized upon completion of the OVA1, Overa or OVA1PLUS test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the quarter ended March 31, 2020, there were approximately $14,000 of downward adjustments to estimates to recognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the quarters ended March 31, 2020 and 2019. Product Revenue – ASPiRA GenetiX: Under ASC 606, the Company’s genetics revenue is recognized upon completion of the ASPiRA GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factor s relating to ASPiRA GenetiX. Service Revenue : The Company’s service revenue was generated by performing IVD trial services for third-party customers. Measurement of progress on contracts with customers was generally based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. We do not expect to have any significant service revenue going forward as we wound down the ASPiRA IVD subsidiary in the fourth quarter of 2019.  Recent Accounting Pronouncements In June 2016 , the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2023 for smaller reporting companies. The Company is currently assessing the impact of this ASU on its consolidated financial statements.  

Agreements With Quest Diagnosti

Agreements With Quest Diagnostics Incorporated	3 Months Ended
	Mar. 31, 2020
Agreements With Quest Diagnostics Incorporated [Abstract]
Agreements With Quest Diagnostics Incorporated	2. AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED  In March 2015, the Company entered into a commercial agreement with Quest Diagnostics, Incorporated (“Quest Diagnostics”) . Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of April 10, 2015, March 11, 2017, March 1, 2018 and March 11, 2020, Quest Diagnostics has continued to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing in exchange for a market value fee.

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments And Contingencies [Abstract]
Commitments And Contingencies	3. COMMITMENTS AND CONTINGENCIES  Coronavirus Aid, Relief, and Economic Security (CARES) Act and Paycheck Protection Program Loan On March 27, 2020, the U.S federal government enacted the CARES Act. The CARES Act is an emergency economic stimulus package in response to the coronavirus outbreak. The Company continues to evaluate the impact of the CARES Act on its business, future financial condition and results of operations but, with the exception of the PPP Loan described below, did not note a material impact of the CARES Act for the three months ended March 31, 2020. On May 1, 2020, we obtained the PPP Loan from BBVA USA in the aggregate amount of $1,005,767 , pursuant to the PPP, which was established under the CARES Act, as administered by the SBA. The application for these funds required the Company to, in good faith, certify that the described economic uncertainty at the time made the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that was not significantly detrimental to the business. Under the terms of the CARES Act and the PPP, all or a portion of the principal amount of the PPP Loan is subject to forgiveness so long as, over the eight-week period following our receipt of the proceeds of the PPP Loan, the Company uses those proceeds for payroll costs, rent, utility costs or the maintenance of employee and compensation levels. The PPP Loan, which was granted pursuant to a Promissory Note, matures on May 1, 2022 . Any unforgiven portion of the PPP Loan bears interest at a rate of 1.000 % per annum, payable monthly in equal installments commencing on December 1, 2020. Development Loan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. On each of March 7, 2018 and April 3, 2020, the Company amended the Loan Agreement to adjust the future milestones which would allow the Company to continue to be eligible to borrow the remaining $2,000,000 . The April 2020 amendment changes the criteria for receiving the next $1,000,000 available under the Loan Agreement by reducing from 40 to 25 the number of full-time employees that the Company is required to hire, by changing the date on or before which the Company must meet this requirement from March 1, 2021 to December 31, 2020, and by increasing the required capital investment of the Company from $18,000,000 to $18,800,000 . Although the criteria for receiving the final $1,000,000 available under the loan were not changed as part of the April 2020 amendment, such disbursement is also conditioned on the Company meeting the requirements described above. Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $1,500,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by December 31, 2022. Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring 25 full-time employees with a specified average annual salary on or before December 31, 2020 or retaining such employees for a consecutive two -year period or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded loan. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory that was used by ASPiRA IVD is located in Trumbull, Connecticut. The Austin, Texas lease expires on January 31, 2021 with no automatic renewal or renewal option. In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000 . The Company has the right to renew the lease for up to two five -year terms at a rate equal to 90% of the then current fair market rate. The Company’s Trumbull, Connecticut lease expires on June 8, 2021. The Company is not reasonably certain to exercise the renewal option for its Trumbull, Connecticut lease due to the uncertain nature of its pricing. The expense associated with these operating leases for the three months ended March 31, 2020 and 2019 is shown in the table below (in thousands).     Three Months Ended March 31  Lease Cost Classification 2020 2019  Operating rent expense  Cost of revenue $ 15 $ 9  Research and development 11 4  Sales and marketing 6 8  General and administrative 14 11   Variable rent expense  Cost of revenue $ 3 $ 12  Research and development 1 3  Sales and marketing 11 10  General and administrative 14 14  Based on our leases as of March 31, 2020, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands).    2020 $ 24  2021 15  2022 2  2023 3  2024 4  2025 1  Total Operating Lease Payments 49  Less: Interest (10)  Present Value of Lease Liabilities 39   Weighted-average lease term and discount rate were as follows:    Weighted-average remaining lease term (in years) 2.2  Weighted-average discount rate 7.75%  Non-cancelable Royalty Obligations The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human disease . Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500 . Royalty expense for the three months ended March 31, 2020 and 2019 totalled $46,000 and $31,000 , respectively.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity:
Stockholders' Equity	4. STOCKHOLDERS’ EQUITY  2019 Offering On June 26, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C., as the sole underwriter (the “Underwriter”), in connection with an underwritten public offering of 18,750,000 shares of the Company’s common stock, par value $0.001 per share. Pursuant to the Underwriting Agreement, the Company agreed to issue and sell an aggregate of 18,750,000 shares of Vermillion common stock offered by the Underwriter in a public offering at a price of $0.80 per share (the “Offering”). The Offering closed on June 28, 2019 and resulted in net proceeds to the Company, of approximately $13,521,000 after deducting expenses of approximately $1,500,000 . Under the Underwriting Agreement, the Company granted the Underwriter an option to purchase up to an additional 2,812,500 shares of Vermillion common stock at the public offering price, less underwriting discounts and commissions. On July 2, 2019, the Underwriter exercised its option to purchase 2,812,500 shares of Vermillion common stock at a price of $0.80 per share and resulted in proceeds to the Company of $2,092,000, after deducting underwriting discounts, commissions and other expenses related to the offering . 2010 Stock Incentive Plan The Company’s employees, directors, and consultants were eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan, which was replaced by the 2019 Plan (as defined below) with respect to future equity grants. As of March 31, 2020, a total of 5,860,377 shares of Vermillion common stock were reserved with respect to outstanding stock options and unvested restricted stock awards.  2019 Stock Incentive Plan At the Company’s annual meeting of stockholders on June 18, 2019, the Company’s stockholders approved the Vermillion, Inc. 2019 Stock Incentive Plan (the “2019 Plan”). The purposes of the 2019 Plan are (i) to align the interests of the Company’s stockholders and recipients of awards under the 2019 Plan by increasing the proprietary interest of such recipients in the Company’s growth and success; (ii) to advance the interests of the Company by attracting and retaining non-employee directors, officers, other employees, consultants, independent contractors and agents; and (iii) to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2019 Plan allows the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to participants. Subject to the terms and conditions of the 2019 Plan, the initial number of shares authorized for grants under the 2019 Plan is 10,492,283 . To the extent an equity award granted under the 2019 Plan expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares of common stock subject to such award will become available for future grant under the 2019 Plan. As of March 31, 2020, a total of 10,492,283 shares of common stock had been reserved for issuance under the 2019 Plan, of which 3,515,708 shares of common stock are subject to outstanding stock options .  Stock-Based Compensation During the three months ended March 31, 2020 , the Company awarded the Company’s non-employee directors an aggregate of 356,940 shares of restricted stock under the 2019 Plan, having a grant date of March 19, 2020 and a grant date fair value of approximately $243,000 . The vesting of these shares of restricted stock is as follows: 25% on April 1, 2020; 25% on June 1, 2020; 25% on September 1, 2020; and 25% on December 1, 2020. During the three months ended March 31, 2020, the Company also granted the Company’s non-employee directors options to purchase an aggregate of 498,768 shares of Vermillion common stock with an exercise price of $0.68 per share. During the three months ended March 31, 2020, the Company granted certain consultants options to purchase 50,000 shares of Vermillion common stock under the 2019 Plan. with an exercise price of $0.82 per share. These stock options have performance-based vesting conditions based on certain metrics through March 31, 2021 . The Company also granted certain consultants options to purchase an aggregate of 41,000 shares of Vermillion common stock with an exercise price of $0.68 per share. During the three months ended March 31, 2020, the Company granted certain officers and employees options to purchase an aggregate of 850,000 shares of Vermillion common stock with an exercise price of $0.82 per share. These stock options were granted under the 2019 Plan and have performance-based vesting conditions based on certain metrics through March 31, 2021 . During the three months ended March 31, 2020, the Company granted certain officers and employees options to purchase an aggregate of 24,000 shares of Vermillion common stock with an exercise price of $0.77 per share and 1,500,000 shares of Vermillion common stock with an exercise price of $0.68 per share. These stock options were granted under the 2019 Plan and vest 25% on each of the four anniversaries of the vesting commencement date for each such stock option. The allocation of employee stock-based compensation expense by functional area for the three months ended March 31, 2020 and 2019 was as follows:   Three Months Ended  March 31,  (in thousands) 2020 2019  Cost of revenue $ 23 $ 12  Research and development — 2  Sales and marketing 37 20  General and administrative 201 143  Total $ 261 $ 177 

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2020
Loss Per Share [Abstract]
Loss Per Share	5. LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of shares of Vermillion common stock outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of Vermillion common stock outstanding and excludes the effects of 12,543,364 and 10,144,433 potential shares of Vermillion common stock as of March 31, 2020 and 2019, respectively, that are anti-dilutive. Potential shares of Vermillion common stock include incremental shares of Vermillion common stock issuable upon the exercise of outstanding warrants, stock options and unvested restricted stock units.

Organization, Basis Of Presen_2

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)	3 Months Ended
	Mar. 31, 2020
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company ,” “we,” “our ,” or “us”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1,Overa and OVA1PLUS risk of malignancy tests for ovarian cancer (“OVA1,” “Overa,” and “OVA1PLUS,” respectively) through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. The Company has historically also offered in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD was a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. The Company has discontinued pursuing contracts for ASPiRA IVD and its contractual commitments were concluded in the fourth quarter of 2019.
Liquidity	Liquidity The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $425,867,000 and limited liquidity at March 31, 2020. The Company also expects to incur a net loss and negative cash flows from operations for 2020. Given these conditions, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date these consolidated financial statements are issued . The consolidated financial statements have been prepared on a going concern basis and do not contain any adjustments as a result of these uncertainties . In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. In addition, many conventions and industry conferences have been canceled. As a result of the COVID-19 pandemic and actions taken to contain it, our test volume , and resulting revenue, has decreased significantly in late March and April 2020 as fewer patients are visiting their physicians and elective surgeries have been postponed as a result of closures. A lthough we have seen some increases in late April and early May 2020 , it is uncertain what the duration of the decreased test volumes might be. In order to reduce the impact of limitations on visiting physician offices due to the current closures and quarantines, we have implemented other means of coverage such as virtual sales representative meetings and increased digital sales and marketing. E nrollment for future studies may also be delayed due to the impact of current closures. The full impact of the COVID-19 pandemic continues to evolve as of the date of this filing. As a result, we are unable to estimate the extent of the impact of the COVID-19 pandemic on our liquidity. As discussed in Note 4, on June 28, 2019, the Company completed a public offering (the “Offering”), pursuant to which certain investors purchased Vermillion common stock for net proceeds of approximately $13,521,000 after deducting underwriting discounts, commissions and other expenses related to the offering. On July 2, 2019, William Blair & Company, L.L.C., the sole underwriter of the Offering, exercised its option to purchase additional shares of Vermillion common stock for net proceeds of $2,092,000 , after deducting underwriting discounts, commissions and other expenses related to the offering. As discussed in Note 3, in March 2016, the Company entered into an agreement (as amended, the “Loan Agreement”), pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (the “DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty. As discussed in Note 3, on May 1, 2020, the Company obtained a loan (the “PPP Loan”) from BBVA USA in the aggregate amount of $1,005,767 , pursuant to the Paycheck Protection Program (the “PPP”), which was established under the Coronavirus Aid, Relief, and Economic Security Act (the “ CARES Act”), as administered by the U.S. Small Business Administration (the “SBA”). 
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December 31, 2019 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in Vermillion’s Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on April 7, 2020 (the “2019 Annual Report”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. In August 2018, the Financial Accounting Standards Board (the “ FASB ”) issued ASU 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2018-15 effective on January 1, 2020, using the prospective transition approach, which allows the Company to change the accounting method without restating prior periods or booking cumulative adjustments. The adoption of ASU 2018-15 did not have a material impact on the Company’s consolidated financial statements.
Revenue Recognition	Revenue Recognition Product Revenue – OVA1, Overa and OVA1PLUS: The Company recognizes product revenue in accordance with the provisions of ASC Topic 606, Revenue from Contracts with Customers (“ ASC 606”) . Product revenue is recognized upon completion of the OVA1, Overa or OVA1PLUS test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the quarter ended March 31, 2020, there were approximately $14,000 of downward adjustments to estimates to recognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the quarters ended March 31, 2020 and 2019. Product Revenue – ASPiRA GenetiX: Under ASC 606, the Company’s genetics revenue is recognized upon completion of the ASPiRA GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factor s relating to ASPiRA GenetiX. Service Revenue : The Company’s service revenue was generated by performing IVD trial services for third-party customers. Measurement of progress on contracts with customers was generally based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. We do not expect to have any significant service revenue going forward as we wound down the ASPiRA IVD subsidiary in the fourth quarter of 2019.
Recent Accounting Pronouncements	 Recent Accounting Pronouncements In June 2016 , the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2023 for smaller reporting companies. The Company is currently assessing the impact of this ASU on its consolidated financial statements. 

Commitments And Contingencies (

Commitments And Contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments And Contingencies [Abstract]
Expense Associated with Operating Leases	   Three Months Ended March 31  Lease Cost Classification 2020 2019  Operating rent expense  Cost of revenue $ 15 $ 9  Research and development 11 4  Sales and marketing 6 8  General and administrative 14 11   Variable rent expense  Cost of revenue $ 3 $ 12  Research and development 1 3  Sales and marketing 11 10  General and administrative 14 14 
Future Lease Payments Related to Operating Leases	  2020 $ 24  2021 15  2022 2  2023 3  2024 4  2025 1  Total Operating Lease Payments 49  Less: Interest (10)  Present Value of Lease Liabilities 39 
Weighted-Average Lease Term and Discount Rate	   Weighted-average remaining lease term (in years) 2.2  Weighted-average discount rate 7.75% 

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity:
Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area	  Three Months Ended  March 31,  (in thousands) 2020 2019  Cost of revenue $ 23 $ 12  Research and development — 2  Sales and marketing 37 20  General and administrative 201 143  Total $ 261 $ 177 

Organization, Basis Of Presen_3

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)	Jul. 02, 2019USD ($)	Jun. 28, 2019USD ($)item	Apr. 15, 2016USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)country	May 01, 2020USD ($)	Mar. 22, 2016USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit				$ 425,867,000		$ 422,161,000
Number of completed public offerings | item		1
Proceeds from public offering	$ 2,092,000	$ 13,521,000
Downward adjustments to recognize revenue for services provided in a prior period				14,000
Impairment losses				0	$ 0
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Number of countries novel coronavirus has spread | country						100
DECD [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
DECD maximum borrowing capacity								$ 4,000,000
DECD initial disbursement			$ 2,000,000
DECD remaining borrowing capacity				$ 2,000,000				$ 2,000,000
BBVA USA [Member] | CARES Act [Member] | Subsequent Event [Member] | Paycheck Protection Program Loan (PPP) [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Aggregate amount of loan granted							$ 1,005,767

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)	May 01, 2020USD ($)	Apr. 03, 2020USD ($)employee	Apr. 15, 2016USD ($)	Mar. 22, 2016USD ($)employee	Mar. 31, 2020USD ($)item	Mar. 31, 2019USD ($)	Mar. 07, 2018USD ($)	Oct. 31, 2015USD ($)
Commitments And Contingencies [Line Items]
Percent of royalty paid					4.00%
Minimum royalty payment					$ 57,500
Royalty expense					$ 46,000	$ 31,000
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Leasehold improvements								$ 596,000
Lease renewal term					5 years
Maximum [Member] | Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Lessee operating lease frequency of renewal terms | item					2
BBVA USA [Member] | Subsequent Event [Member] | CARES Act [Member] | Paycheck Protection Program Loan (PPP) [Member]
Commitments And Contingencies [Line Items]
Aggregate amount of loan granted	$ 1,005,767
Fixed rate per annum	1.00%
Maturity date	May 1, 2022
DECD [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity				$ 4,000,000
Fixed rate per annum				2.00%
Maturity date					Apr. 15, 2026
Amount eligible for forgiveness				$ 1,500,000
DECD initial disbursement			$ 2,000,000
DECD remaining borrowing capacity				$ 2,000,000	$ 2,000,000
DECD [Member] | Amended Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Job creation, consecutive period of hiring and retaining				2 years
Debt, maturity term					10 years
Debt penalty percentage					5.00%
Line of Credit [Member] | DECD [Member]
Commitments And Contingencies [Line Items]
Number of full-time employees required to hire | employee				40
Capital investment required to meet loan criteria				$ 18,000,000
Line of Credit [Member] | DECD [Member] | Amended Loan Agreement [Member]
Commitments And Contingencies [Line Items]
DECD remaining borrowing capacity							$ 2,000,000
Line of Credit [Member] | DECD [Member] | Subsequent Event [Member] | Amended Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Number of full-time employees required to hire | employee		25
Capital investment required to meet loan criteria		$ 18,800,000
DECD remaining borrowing capacity		2,000,000
Line of Credit [Member] | DECD [Member] | Subsequent Event [Member] | First Loan Available Under Loan Agreement [Member] | Amended Loan Agreement [Member]
Commitments And Contingencies [Line Items]
DECD remaining borrowing capacity		1,000,000
Line of Credit [Member] | DECD [Member] | Subsequent Event [Member] | Final Loan Available Under Loan Agreement [Member] | Amended Loan Agreement [Member]
Commitments And Contingencies [Line Items]
DECD remaining borrowing capacity		$ 1,000,000

Commitments And Contingencies_3

Commitments And Contingencies (Expense Associated with Operating Leases) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cost Of Revenue [Member]
Operating rent expense	$ 15	$ 9
Variable rent expense	3	12
Research And Development [Member]
Operating rent expense	11	4
Variable rent expense	1	3
Sales And Marketing [Member]
Operating rent expense	6	8
Variable rent expense	11	10
General And Administrative [Member]
Operating rent expense	14	11
Variable rent expense	$ 14	$ 14

Commitments And Contingencies_4

Commitments And Contingencies (Future Lease Payments Related to Operating Leases) (Details) $ in Thousands	Mar. 31, 2020USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2020	$ 24
2021	15
2022	2
2023	3
2024	4
2025	1
Total Operating Lease Payments	49
Less: Interest	(10)
Present Value of Lease Liabilities	$ 39

Commitments And Contingencies_5

Commitments And Contingencies (Weighted-Average Lease Term and Discount Rate) (Details)	Mar. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term (in years)	2 years 2 months 12 days
Weighted-average discount rate	7.75%

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	Jul. 02, 2019	Jun. 28, 2019	Mar. 31, 2020	Dec. 31, 2019	Jun. 26, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued			97,288,657	97,286,157
Net proceeds from public offering	$ 2,092,000	$ 13,521,000
Common stock, par value			$ 0.001	$ 0.001
Preferred stock, shares issued			0	0
Preferred stock, par value			$ 0.001	$ 0.001
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares authorized for grants			10,492,283
Share based compensation shares reserved for issuance			10,492,283
2019 Stock Incentive Plan [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			3,515,708
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance			5,860,377
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares granted			356,940
Fair value of restricted share units			$ 243,000
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | April 1, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | June 1, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | September 1, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | December 1, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | $0.68 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			498,768
Stock options granted, average exercise price			$ 0.68
2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | $0.82 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			50,000
Stock options granted, average exercise price			$ 0.82
2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | $0.68 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			41,000
Stock options granted, average exercise price			$ 0.68
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.82 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			850,000
Stock options granted, average exercise price			$ 0.82
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.77 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			24,000
Stock options granted, average exercise price			$ 0.77
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.68 [Member] | Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted			1,500,000
Stock options granted, average exercise price			$ 0.68
2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $0.68 [Member] | Stock Option [Member] | Year Four Anniversary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
2019 Offerings [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued	2,812,500				18,750,000
Price per share	$ 0.80
Underwriting agreement, per share					$ 0.80
Underwriting agreement					18,750,000
Net proceeds from public offering	$ 2,092,000	13,521,000
Underwriting discounts, commissions and other expenses related to the offering		$ 1,500,000
Common stock, par value					$ 0.001
2019 Offerings [Member] | Common Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriting commitments additional shares offered					2,812,500

Stockholders' Equity (Allocatio

Stockholders' Equity (Allocation of Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 25	$ 16
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense		2
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	42	22
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	202	144
Employee Stock-Based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	261	177
Employee Stock-Based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	23	12
Employee Stock-Based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense		2
Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	37	20
Employee Stock-Based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 201	$ 143

Loss Per Share (Details)

Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Loss Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	12,543,364	10,144,433